Latest / Cyrona Cell Podcast: Stem Cell Therapy in Malaysia / TBI Inflammation: Where Regenerative Medicine May Fit
Transcript
- 0:00SPEAKER_01: Welcome to the Sirona Cell Podcast.
- 0:02SPEAKER_01: Imagine you're in a uh a minor car accident.
- 0:06SPEAKER_01: You know, you bump your head against the steering wheel.
- 0:08SPEAKER_00: Aaron Ross Powell Right, something fairly common.
- 0:10SPEAKER_01: Yeah, exactly.
- 0:11SPEAKER_01: You go to the hospital, you get a scan, and eventually you're clear to go home.
- 0:16SPEAKER_01: And you think it's over, right?
- 0:18SPEAKER_01: You'd certainly hope so.
- 0:19SPEAKER_01: Aaron Ross Powell But what if I told you that the actual injury hasn't even finished happening yet?
- 0:24SPEAKER_01: What if your brain's internal defense system just declared this like biological war that might last for the next 10 years?
- 0:31SPEAKER_00: Aaron Powell It's a profound shift in how we view neurological trauma.
- 0:34SPEAKER_00: We're no longer looking at an event or looking at a cascade.
- 0:38SPEAKER_01: Aaron Powell And that cascade is exactly what we're focusing our mission on for today's deep dive.
- 0:43SPEAKER_01: We're unpacking this fascinating blog article from Cyrone Cell titled TBI Inflammation, where regenerative medicine may fit.
- 0:51SPEAKER_00: It's a great piece.
- 0:51SPEAKER_01: Aaron Powell It really is.
- 0:52SPEAKER_01: So we're going to explore what actually happens inside the human brain long after a physical impact occurs and how cutting edge science is trying to intervene.
- 1:01SPEAKER_00: Right.
- 1:02SPEAKER_01: So whether you are a medical professional or someone actively dealing with a TBI, or just wildly curious about biology, understanding inflammation after a brain injury is going to completely change how you view head trauma.
- 1:15SPEAKER_00: Aaron Powell I do want to set a clear baseline for you right from the start, though.
- 1:18SPEAKER_01: Oh, for sure.
- 1:19SPEAKER_00: We are looking at a space where biology meets an evolving, highly complex frontier.
- 1:24SPEAKER_00: The sources we're examining present a very cautious analytical look at the field.
- 1:28SPEAKER_01: Aaron Powell Yeah, this isn't magic.
- 1:29SPEAKER_00: Aaron Powell Exactly.
- 1:30SPEAKER_00: We are exploring ongoing science here.
- 1:32SPEAKER_00: These are not guaranteed cures you can just pick up at a pharmacy.
- 1:35SPEAKER_00: They're underlying mechanisms that researchers are just beginning to decode.
- 1:39SPEAKER_01: Aaron Powell And we have to be honest about the bottlenecks, too.
- 1:42SPEAKER_00: Aaron Powell We do.
- 1:42SPEAKER_00: Aaron Ross Powell The clinical data offers genuine, incredible potential, but it comes with significant unsolved biological hurdles that we really have to talk about openly.
- 1:51SPEAKER_01: Aaron Powell So what does this all actually mean?
- 1:54SPEAKER_01: To understand how regenerative medicine might even play a role here, we kind of have to throw out our conventional definition of a brain injury.
- 2:01SPEAKER_01: Trevor Burrus, Jr.
- 2:01SPEAKER_00: Throw it right out the window.
- 2:02SPEAKER_01: Aaron Ross Powell Right.
- 2:03SPEAKER_01: We usually think of a traumatic brain injury, a TBI, as a one-and-done situation.
- 2:08SPEAKER_01: But the direct mechanical force, you know, the physics of the impact, that's just the primary injury.
- 2:14SPEAKER_00: Aaron Powell Yes.
- 2:15SPEAKER_00: The primary injury is physics.
- 2:17SPEAKER_00: The secondary injury is biology.
- 2:19SPEAKER_01: Aaron Ross Powell And that secondary one unfolds over hours, days, and even years.
- 2:23SPEAKER_00: Aaron Ross Powell Exactly.
- 2:24SPEAKER_00: Following that initial trauma, the brain's internal environment is thrown into total chaos.
- 2:29SPEAKER_00: And to understand how that chaos sustains itself, we have to look at two specific types of cells.
- 2:34SPEAKER_01: Aaron Ross Powell The residence cells?
- 2:35SPEAKER_00: Right.
- 2:35SPEAKER_00: Microglia and astrocytes.
- 2:37SPEAKER_00: So microglia are essentially the brain's specialized immune cells.
- 2:41SPEAKER_00: They act as sentinels.
- 2:42SPEAKER_01: Like security guards.
- 2:43SPEAKER_00: Aaron Powell Basically, yeah.
- 2:44SPEAKER_00: Their normal job is to just wander around, sense damage, and clear away cellular debris after a minor injury.
- 2:50SPEAKER_01: Aaron Powell And the astrocytes?
- 2:51SPEAKER_00: Astrocytes are the support cells.
- 2:53SPEAKER_00: They maintain the chemical environment around your neurons.
- 2:56SPEAKER_00: In a normal, healthy response, both these cell types do their job, clean up the mess, and get a chemical signal to power down.
- 3:02SPEAKER_01: Aaron Powell But in a severe TBI, that power down signal just gets lost, doesn't it?
- 3:07SPEAKER_00: It completely vanishes.
- 3:08SPEAKER_01: I read this and I immediately thought about it like uh like hiring a demolition crew to clear out a broken kitchen cabinet.
- 3:15SPEAKER_00: Aaron Powell Oh, that's a good way to look at it.
- 3:16SPEAKER_01: Trevor Burrus, Jr.
- 3:17SPEAKER_01: Right.
- 3:17SPEAKER_01: You want them to come in, remove the splintered wood, and leave.
- 3:20SPEAKER_01: But in this secondary injury phase, they never get the memo that the job is done.
- 3:25SPEAKER_00: They just keep going.
- 3:26SPEAKER_01: Yeah.
- 3:26SPEAKER_01: They keep working, and eventually they end up taking sledgehammers to your plumbing and your foundation for years.
- 3:32SPEAKER_00: Aaron Ross Powell That analogy captures the mechanism perfectly.
- 3:35SPEAKER_00: And to extend it a bit, they don't just keep swinging sledgehammers.
- 3:38SPEAKER_00: They actively start throwing the debris into your pipes.
- 3:41SPEAKER_01: Oh wow.
- 3:42SPEAKER_01: Just making it worse.
- 3:44SPEAKER_00: Much worse.
- 3:45SPEAKER_00: In a severe TBI, the tissue damage is so vast that the massive amount of debris overwhelms the microglia.
- 3:52SPEAKER_00: They panic.
- 3:52SPEAKER_01: Aaron Ross Powell So they're frantically trying to clear it.
- 3:54SPEAKER_00: Aaron Ross Powell Right.
- 3:55SPEAKER_00: And as they do, they release inflammatory cytokines, which are these chemical alarms.
- 3:59SPEAKER_00: But those alarms inadvertently kill the surrounding healthy neurons.
- 4:03SPEAKER_01: Aaron Ross Powell Which just creates more debris.
- 4:05SPEAKER_00: Trevor Burrus Exactly.
- 4:06SPEAKER_00: It creates fresh debris, which keeps the microglia panicked.
- 4:09SPEAKER_00: It becomes this vicious, self-sustaining loop.
- 4:12SPEAKER_01: Aaron Powell And what are the astrocytes doing during all this?
- 4:16SPEAKER_00: Aaron Powell They respond by forming thick, dense physical scars to wall off the damage.
- 4:21SPEAKER_00: And that physical scarring actually prevents new neural connections from forming.
- 4:27SPEAKER_01: But I'm struggling with a timeline here, to be honest.
- 4:30SPEAKER_01: I mean, eventually a demolition crew runs out of energy or just goes home.
- 4:34SPEAKER_00: Aaron Powell You would think so.
- 4:35SPEAKER_01: Aaron Powell Are you saying these immune cells are just sitting in the brain actively attacking healthy tissue for a decade?
- 4:43SPEAKER_01: How do we even know that?
- 4:44SPEAKER_01: You can't just open a patient's skull 10 years later to check the plumbing.
- 4:48SPEAKER_00: Well, you don't have to open the skull because we have advanced imaging now.
- 4:51SPEAKER_00: The visual evidence proving this timeline comes from PET imaging studies.
- 4:54SPEAKER_01: Aaron Powell The PET scans.
- 4:56SPEAKER_00: Right.
- 4:56SPEAKER_00: A PET scan uses a mildly radioactive tracer that binds to specific active molecules.
- 5:02SPEAKER_00: Researchers actually developed tracers that light up specifically when microglia are in that aggressive inflammatory state.
- 5:10SPEAKER_01: Oh, that's brilliant.
- 5:11SPEAKER_00: It is.
- 5:11SPEAKER_00: And when they scan patients far, far past the original trauma, the results are just staggering.
- 5:17SPEAKER_00: Aaron Powell Yeah.
- 5:18SPEAKER_01: Here's where it gets really interesting.
- 5:20SPEAKER_01: One review highlighted in the article found signs of this destructive immune activity more than a decade later.
- 5:26SPEAKER_01: Over 10 years.
- 5:37SPEAKER_00: What's fascinating here is the disparity in how the body handles different severities of trauma.
- 5:42SPEAKER_00: Mild cases often resolve within a few weeks.
- 5:44SPEAKER_01: Right.
- 5:44SPEAKER_01: The brain just goes back to normal.
- 5:46SPEAKER_01: Trevor Burrus, Jr.
- 5:46SPEAKER_00: Exactly, leaving no lasting trace on a PET scan.
- 5:49SPEAKER_00: But severe or repetitive injuries seem to break that biological feedback loop entirely.
- 5:54SPEAKER_01: Aaron Powell Leaving that window open.
- 5:56SPEAKER_00: Yes.
- 5:56SPEAKER_00: They leave this window of immune activation open far longer than science previously assumed.
- 6:01SPEAKER_00: And the clinical data clearly links this prolonged activation to worse long-term outcomes.
- 6:06SPEAKER_01: Aaron Powell So the longer those cells are inflamed, the worse the patient does?
- 6:10SPEAKER_00: Precisely.
- 6:11SPEAKER_00: Their cognitive and motor functions tend to degrade over time.
- 6:14SPEAKER_01: Aaron Powell I have to push back on this a little bit though.
- 6:16SPEAKER_01: Sure.
- 6:16SPEAKER_01: If you end up in the ICU with a severe head injury today, standard medical care is incredible.
- 6:22SPEAKER_01: They monitor your pressure, keep you stable, give you meds.
- 6:25SPEAKER_01: Aaron Ross Powell It is incredible, yes.
- 6:26SPEAKER_01: Aaron Ross Powell So if standard care is so highly advanced, why does it completely miss this decade-long immune cascade?
- 6:33SPEAKER_00: Aaron Ross Powell Because standard medical care is exquisitely designed for acute crisis management, not long-term cellular modulation.
- 6:40SPEAKER_01: Oh, I see.
- 6:41SPEAKER_00: In the ICU, the goal is just to keep you alive today.
- 6:44SPEAKER_00: The drugs they use are systemic, they target global pathways to reduce life-threatening swelling and stop you from bleeding out.
- 6:50SPEAKER_01: So they're blunt instruments.
- 6:52SPEAKER_00: Very blunt.
- 6:53SPEAKER_00: They're not designed to enter the brain and delicately turn down a highly complex cellular feedback loop over the course of years.
- 6:59SPEAKER_01: So once you survive the crisis, you're on your own.
- 7:03SPEAKER_00: Essentially, yes.
- 7:04SPEAKER_00: The brain is left to reset its own immune system.
- 7:06SPEAKER_00: And as those PET scans show, for many people, it fundamentally fails to do so.
- 7:10SPEAKER_01: Aaron Powell Okay.
- 7:11SPEAKER_01: Let's unpack this.
- 7:12SPEAKER_01: Since standard care leaves this massive gap, this is exactly where regenerative medicine is trying to step in, right?
- 7:19SPEAKER_00: Aaron Ross Powell That's the idea.
- 7:20SPEAKER_01: Aaron Powell But it's crucial to note that the goal here isn't what people usually picture when they hear stem cells.
- 7:26SPEAKER_01: They picture scientists building a new brain out of clay.
- 7:29SPEAKER_00: Aaron Powell Right, replacing lost parts.
- 7:31SPEAKER_01: Yeah.
- 7:32SPEAKER_01: But the objective is modulation, not replacement.
- 7:35SPEAKER_01: The therapy aims to calm the immune system down and support the brain's existing repair signals.
- 7:40SPEAKER_00: Aaron Powell Exactly.
- 7:41SPEAKER_00: The mechanism of action here is chemical signaling.
- 7:45SPEAKER_00: The cells introduced in these therapies aren't building blocks meant to replace dead neurons.
- 7:48SPEAKER_00: They're biological factories.
- 7:50SPEAKER_01: Aaron Ross Powell So they just pump out chemicals?
- 7:52SPEAKER_00: Aaron Ross Powell Yes.
- 7:53SPEAKER_00: Once introduced, they sense the inflammatory environment and begin releasing highly specific growth factors into the surrounding tissue.
- 7:59SPEAKER_01: Aaron Powell The sources detail two critical ones, BDNF and VEGF.
- 8:04SPEAKER_00: Aaron Ross Powell Right.
- 8:05SPEAKER_00: Brain-derived neurotrophic factor and vascular endothelial growth factor.
- 8:10SPEAKER_01: Aaron Ross Powell And what do those actually do, like on a cellular level?
- 8:13SPEAKER_00: Aaron Ross Powell So BDNF acts as a profound survival signal for stressed neurons.
- 8:18SPEAKER_00: Think of it like a specialized fertilizer.
- 8:20SPEAKER_01: Aaron Powell Oh, I like that.
- 8:21SPEAKER_00: It essentially instructs dying neurons to stay alive, stabilize, and start repairing their broken connections.
- 8:26SPEAKER_01: Aaron Powell And the VEGEF?
- 8:28SPEAKER_00: VEGEF stimulates the formation of brand new blood vessels.
- 8:31SPEAKER_00: It prompts existing capillary walls to sprout new branches, which restores healthy, oxygen-rich blood flow to suffocating tissue.
- 8:38SPEAKER_01: Aaron Powell So they work together to rescue the tissue.
- 8:40SPEAKER_01: Trevor Burrus, Jr.
- 8:41SPEAKER_00: Exactly.
- 8:41SPEAKER_00: They pull it back from the brink of cell death.
- 8:43SPEAKER_01: Aaron Ross Powell The sources also talk about extracellular vesicles, which I mean completely blew my mind.
- 8:48SPEAKER_00: Aaron Powell They're a game changer.
- 8:49SPEAKER_01: Trevor Burrus, Jr.
- 8:50SPEAKER_01: They're these tiny microscopic packages that the introduced stem cells release into the environment, and they carry all these calming signals.
- 8:58SPEAKER_01: It's like it's like airdropping thousands of tiny chemical peace treaties across a battlefield.
- 9:02SPEAKER_00: Aaron Powell That is a brilliant way to visualize it.
- 9:05SPEAKER_00: And to take that airdrop analogy further, those peace treaties can slip past enemy lines in ways the actual cargo planes cannot.
- 9:12SPEAKER_00: Trevor Burrus, Jr.
- 9:12SPEAKER_01: Because of their size.
- 9:13SPEAKER_00: Right.
- 9:13SPEAKER_00: Extracellular vesicles solve a massive spatial problem.
- 9:17SPEAKER_00: A single stem cell is physically quite large and can only touch a few neighboring cells.
- 9:21SPEAKER_01: It gets stuck.
- 9:22SPEAKER_00: Yes, but these vesicles are tiny lipid bubbles.
- 9:25SPEAKER_00: They can travel freely through dense brain tissue, penetrate deep into inflamed areas, and deliver regulatory signals to hostile cells that the parent stem cell could never physically reach.
- 9:34SPEAKER_01: Aaron Powell So it's really about creating an environment where the brain can fix itself.
- 9:39SPEAKER_01: Because as adults, we don't really grow new brain cells, do we?
- 9:42SPEAKER_00: Aaron Ross Powell We do, but in extremely limited quantities and only in very specific regions.
- 9:46SPEAKER_01: Aaron Powell So it's not enough to fix a major injury.
- 9:49SPEAKER_00: Aaron Ross Powell No.
- 9:49SPEAKER_00: Meaningful recovery after severe trauma is rarely about generating new brain matter to fill a physical hole.
- 9:55SPEAKER_00: It's about neuroplasticity.
- 9:56SPEAKER_01: Aaron Ross Powell Rewiring the connections.
- 9:58SPEAKER_00: Aaron Powell Exactly.
- 9:58SPEAKER_00: The brain's ability to physically bypass damaged areas.
- 10:01SPEAKER_00: The chemical support from these growth factors and vesicles is crucial because it calms the inflammation enough to create a permissive environment.
- 10:08SPEAKER_01: It just lets neuroplasticity happen.
- 10:10SPEAKER_00: Precisely.
- 10:11SPEAKER_01: So if this entire treatment relies on delivering these chemical peace treaties, the next logical question you have to ask is which cells are acting as the messengers?
- 10:21SPEAKER_00: Aaron Ross Powell That's the big debate.
- 10:23SPEAKER_01: Right.
- 10:23SPEAKER_01: The research focuses on two main categories, and I I want to make sure I'm grasping the difference here.
- 10:29SPEAKER_01: First, you have neural stem cells, or NSCs.
- 10:32SPEAKER_01: Right.
- 10:32SPEAKER_01: These seem to be the ones trying to actually turn into brain tissue, right?
- 10:35SPEAKER_00: Aaron Powell Theoretically, yes.
- 10:37SPEAKER_00: Neural stem cells are derived from uh central nervous system lineages, so in a highly controlled lab setting, they can differentiate or develop into actual neurons.
- 10:46SPEAKER_01: Aaron Powell So they carry that promise of structural replacement.
- 10:49SPEAKER_00: They do.
- 10:50SPEAKER_00: However, proving that they can reliably do this, survive, and integrate into a living human brain network remains exceedingly difficult.
- 10:58SPEAKER_01: Aaron Powell So the evidence isn't really there yet.
- 11:00SPEAKER_00: Aaron Powell The human clinical evidence for that specific pathway is very limited right now.
- 11:04SPEAKER_01: Aaron Ross Powell Got it.
- 11:06SPEAKER_01: Then you have the other major player uh mesenchymal stem cells, or MSCs.
- 11:10SPEAKER_00: Yes.
- 11:11SPEAKER_01: Trevor Burrus These are sourced from completely outside the brain, like bone marrow, uh fat tissue, or umbilical cord.
- 11:18SPEAKER_01: And my understanding is they aren't trying to become neurons at all.
- 11:21SPEAKER_00: Aaron Powell Precisely.
- 11:22SPEAKER_00: Mesenchymal stem cells rarely, if ever, engraft and become new brain cells.
- 11:27SPEAKER_00: Their value is entirely derived from their pericrine effect.
- 11:30SPEAKER_01: Aaron Ross Powell, which is the chemical signaling we talked about.
- 11:32SPEAKER_00: Trevor Burrus, Jr.
- 11:33SPEAKER_00: Right.
- 11:33SPEAKER_00: The signals and vesicles they release.
- 11:36SPEAKER_00: They are the factories.
- 11:37SPEAKER_00: And because MSCs are far easier to source and expand in a lab without losing their potency, the vast majority of current human research focuses heavily on them.
- 11:45SPEAKER_01: Aaron Powell It's basically the difference between trying to be the brain versus trying to coach the brain.
- 11:50SPEAKER_00: Aaron Powell I like that.
- 11:51SPEAKER_01: Aaron Ross Powell Yeah.
- 11:52SPEAKER_01: Like neural stem cells are the bench players trying to sub into the game, and the mesenchymal stem cells are the coaches on the sidelines, shouting instructions, calming the team down so they can execute the players.
- 12:03SPEAKER_00: Aaron Powell If we connect this to the bigger picture, this exact cellular distinction shapes research across almost every severe central nervous system condition today.
- 12:11SPEAKER_01: Aaron Ross Powell Really?
- 12:12SPEAKER_01: Like what else?
- 12:13SPEAKER_00: Aaron Ross Powell We see the identical debate playing out in spinal cord injury research and stroke recovery.
- 12:19SPEAKER_00: The specific cell type chosen fundamentally dictates the biological strategy.
- 12:24SPEAKER_01: Aaron Powell Shifting away from replacement.
- 12:26SPEAKER_00: Aaron Ross Powell Exactly.
- 12:27SPEAKER_00: Heavily toward inflammatory modulation.
- 12:29SPEAKER_01: Aaron Ross Powell And to weave in some real-world context here, Cyrona Cell, the group that authored the article we're deep diving into, operates exactly in this signaling space.
- 12:38SPEAKER_00: Right.
- 12:38SPEAKER_01: They're based in Kuala Lumpur, treating both local and international patients, and they specifically utilize umbilical cord-derived MSCs.
- 12:46SPEAKER_00: Aaron Ross Powell Often known as WJ MSCs or Wharton's jelly mesenchymal stem cells.
- 12:51SPEAKER_01: Right.
- 12:52SPEAKER_01: So their clinical focus is squarely on this coaching modulation-based approach rather than trying to build new brain tissue.
- 12:59SPEAKER_00: It's a deliberate clinical choice.
- 13:01SPEAKER_00: It's based on where the bulk of actionable safety and efficacy data currently sits in the broader scientific community.
- 13:07SPEAKER_01: Aaron Powell Okay, but let's ground this.
- 13:09SPEAKER_01: Theory and lab studies are fascinating.
- 13:12SPEAKER_01: But what happens when you actually test this on human patients?
- 13:16SPEAKER_00: That's where the rubber meets the road.
- 13:18SPEAKER_01: Aaron Powell Exactly.
- 13:19SPEAKER_01: The sources detail a very notable phase two clinical trial.
- 13:22SPEAKER_01: They used a bone marrow-derived stem cell product on patients with chronic motor deficits following a trauma.
- 13:28SPEAKER_00: Aaron Powell And chronic is the vital keyword there.
- 13:31SPEAKER_01: Aaron Ross Powell Right.
- 13:31SPEAKER_01: It means their symptoms had entirely plateaued.
- 13:34SPEAKER_00: Aaron Powell Yes.
- 13:34SPEAKER_00: In a clinical context, a chronic motor deficit means natural neuroplasticity has totally stalled.
- 13:40SPEAKER_01: The brain's given up.
- 13:41SPEAKER_00: Well, it's settled into a permanently impaired baseline.
- 13:44SPEAKER_00: A patient might have a hand that won't open or a leg that drags, and despite standard physical therapy, it hasn't improved in months or years.
- 13:52SPEAKER_01: Aaron Powell Right.
- 13:53SPEAKER_01: So you take these patients who aren't supposed to get any better, and you introduce this coaching cell therapy.
- 13:59SPEAKER_00: And the results were quite interesting.
- 14:01SPEAKER_01: Very.
- 14:02SPEAKER_01: At the six-month mark, the trial showed the treated group improved by an average of 8.3 points on a standard motor scale.
- 14:10SPEAKER_01: The control group only improved by 2.3 points.
- 14:13SPEAKER_00: A notable difference.
- 14:15SPEAKER_01: But the statistical breakdown is even wilder.
- 14:18SPEAKER_01: Roughly 39% of the treated patients achieved what's classified as a clinically meaningful improvement.
- 14:24SPEAKER_01: Less than 7% of the control group hit that same benchmark.
- 14:27SPEAKER_00: And then just as importantly for the scientific community, the trial reported no significant difference in serious side effects between the two groups.
- 14:34SPEAKER_01: Aaron Powell, which is huge for safety.
- 14:36SPEAKER_00: Exactly.
- 14:36SPEAKER_00: It strongly supports the baseline safety profile of administering the cells.
- 14:40SPEAKER_01: I have to say though, if I'm a listener dealing with a plateaued injury or I'm watching a loved one struggle and I hear a 39% success stat, I'm immediately looking up flights to a clinic.
- 14:50SPEAKER_00: It's very easy to get swept up in that hope.
- 14:53SPEAKER_01: It is.
- 14:54SPEAKER_01: Yet the sources use very hedged, cautious language.
- 14:58SPEAKER_01: Why are we throwing cold water on a 39% improvement rate?
- 15:02SPEAKER_01: Like, why do small sample sizes make the numbers so noisy?
- 15:05SPEAKER_00: Because human biology is inherently wildly variable.
- 15:10SPEAKER_01: In what way?
- 15:11SPEAKER_00: Well, no two physical brain traumas are identical.
- 15:14SPEAKER_00: The shearing forces, the exact location of the micro bleeds, the patient's genetic immune makeup, it all varies.
- 15:21SPEAKER_01: So it's hard to compare patient to patient.
- 15:24SPEAKER_00: Very.
- 15:24SPEAKER_00: And when a clinical trial only enrolls a small handful of patients, which most phase two trials do, a single outlier can severely distort the data.
- 15:33SPEAKER_01: Oh, I see.
- 15:34SPEAKER_01: If one guy just naturally gets better?
- 15:37SPEAKER_00: Exactly.
- 15:38SPEAKER_00: If one person recovers exceptionally well for reasons entirely unrelated to the therapy, it drastically skews the final percentages.
- 15:45SPEAKER_01: Makes sense.
- 15:47SPEAKER_00: A systematic review of the wider field reveals inconsistent results across these smaller studies.
- 15:52SPEAKER_00: Some show great promise, others show minimal effect.
- 15:54SPEAKER_00: Until we have massive trials with hundreds of participants to smooth out that variance, it remains incredibly difficult to isolate the genuine therapeutic effect.
- 16:03SPEAKER_01: Aaron Powell So there's absolutely no guaranteed outcome yet.
- 16:06SPEAKER_00: None.
- 16:06SPEAKER_01: That makes total sense.
- 16:08SPEAKER_01: And it leads perfectly to my next thought.
- 16:10SPEAKER_01: If that phase two trial did show significant motor improvement for some, why isn't this just standard treatment everywhere today?
- 16:17SPEAKER_00: Ah, the bottleneck.
- 16:18SPEAKER_01: Right.
- 16:19SPEAKER_01: The central, unsolved bottleneck.
- 16:21SPEAKER_01: It all comes down to delivery.
- 16:23SPEAKER_01: I mean, you can have the most potent chemical messengers in the world, but they're useless if they can't reach the actual battlefield in the brain.
- 16:30SPEAKER_00: The logistics of cellular delivery present a massive physiological hurdle.
- 16:34SPEAKER_01: Aaron Powell And one of the early studies tested a standard IV infusion, right?
- 16:38SPEAKER_01: Like just putting stem cells in an arm vein?
- 16:41SPEAKER_00: Aaron Powell They did, and the results were stark and disappointing.
- 16:44SPEAKER_00: Fewer than 4% of the infused cells ever reach the brain circulation.
- 16:48SPEAKER_01: Aaron Powell Where do the other 96% go?
- 16:51SPEAKER_00: The vast majority of them became physically trapped in the lungs.
- 16:54SPEAKER_01: Aaron Powell The dreaded lung trap.
- 16:56SPEAKER_01: I love this concept.
- 16:58SPEAKER_01: It's like trying to mail a million letters from New York to California, but the Postal Service dumps 96% of them into a giant sorting warehouse in the Midwest before they ever get near the destination.
- 17:08SPEAKER_01: Aaron Powell That's a perfect analogy.
- 17:10SPEAKER_01: Aaron Powell But why does that happen?
- 17:11SPEAKER_00: Aaron Ross Powell Because of the physical realities of the cells themselves.
- 17:15SPEAKER_00: Mesenchymal stem cells are relatively large and somewhat rigid compared to your flexible red blood cells.
- 17:21SPEAKER_01: Okay.
- 17:21SPEAKER_00: And to get from a vein in your arm to your brain, the blood must first pass through your lungs to get oxygenated.
- 17:27SPEAKER_00: The lungs contain an incredibly dense microscopic network of capillary beds.
- 17:31SPEAKER_01: Aaron Powell So they act like a filter?
- 17:33SPEAKER_00: Aaron Ross Powell Like a physical sieve, yes.
- 17:35SPEAKER_00: The large stem cells simply get wedged in those tiny vessels.
- 17:38SPEAKER_00: And to take your postal analogy further, those letters don't just sit in the warehouse unharmed.
- 17:43SPEAKER_01: Wait, they get destroyed?
- 17:45SPEAKER_00: Often, yes.
- 17:46SPEAKER_00: The body's resident immune cells in the lungs often shred them, recognizing them as foreign cellular matter that needs to be cleared out.
- 17:52SPEAKER_01: Aaron Ross Powell So an IV drip just isn't getting the job done for brain injuries.
- 17:57SPEAKER_00: Unfortunately not.
- 17:58SPEAKER_01: Aaron Ross Powell And because of this, researchers are actively testing far more direct and frankly riskier delivery methods, right?
- 18:05SPEAKER_00: Yes.
- 18:05SPEAKER_00: To bypass that pulmonary first pass effect, the lung trap, researchers are utilizing intraarterial injections.
- 18:12SPEAKER_01: Aaron Powell Which means what exactly?
- 18:14SPEAKER_00: It involves threading a catheter up past the heart to deliver the cells directly into the carotid artery, feeding straight into the brain.
- 18:21SPEAKER_01: Aaron Powell Yikes.
- 18:22SPEAKER_01: That sounds intense.
- 18:24SPEAKER_00: It is.
- 18:25SPEAKER_00: Others are testing direct surgical implantation, drilling into the skull to place the cells right at the lesion site.
- 18:31SPEAKER_01: Aaron Powell It's a massive trade-off.
- 18:32SPEAKER_00: Aaron Powell A calculated serious trade-off.
- 18:34SPEAKER_00: They are trading the high safety margin of a simple arm IV for a vastly improved chance of meaningful cell delivery.
- 18:43SPEAKER_00: But neither approach has fully solved the problem without introducing new risks, like, say, microstrokes from clumped cells in the arteries.
- 18:50SPEAKER_01: Aaron Powell Wow.
- 18:51SPEAKER_01: It really remains the biggest physical barrier in the science right now.
- 18:55SPEAKER_01: Absolutely.
- 18:55SPEAKER_01: But bringing all this complex cellular science back down to the actual patient journey, what should you take away from this deep dive?
- 19:03SPEAKER_01: First, this therapy is not a first-line treatment.
- 19:07SPEAKER_00: Definitely not.
- 19:07SPEAKER_01: You don't bypass the ICU or skip standard rehabilitation to go look for stem cells.
- 19:13SPEAKER_01: It's a later stage conversation, generally explored when standard rehab is plateaued and you're stuck in that chronic phase.
- 19:20SPEAKER_00: And the evaluation process must be highly meticulous.
- 19:24SPEAKER_00: A responsible physician must review recent brain imaging and the comprehensive clinical history of the trauma.
- 19:30SPEAKER_01: Because timing matters.
- 19:31SPEAKER_00: Exactly.
- 19:32SPEAKER_00: The sheer age of the injury heavily dictates how that internal inflammation is behaving today.
- 19:37SPEAKER_00: We see a related pattern in modern stroke treatments.
- 19:40SPEAKER_00: The timing totally alters the biological landscape.
- 19:43SPEAKER_01: And we can't forget about rehab.
- 19:45SPEAKER_00: No.
- 19:45SPEAKER_00: Because the adult brain is rewiring itself rather than growing new tissue.
- 19:50SPEAKER_00: Intensive physical and cognitive rehabilitation remains absolutely central to recovery.
- 19:55SPEAKER_01: They work together.
- 19:57SPEAKER_00: Yes.
- 19:57SPEAKER_00: The cells might provide the chemical fertilizer, but the rehabilitation provides the physical blueprint for where the new neural connections actually need to go.
- 20:05SPEAKER_00: You can't have one without the other.
- 20:07SPEAKER_01: Now, if you are exploring these avenues, you don't have to guess at your candidacy or try to read your own PET scans.
- 20:13SPEAKER_01: You can actually message the Cirona Cell team directly on WhatsApp or submit your case for a free medical review.
- 20:19SPEAKER_00: It's a great starting point.
- 20:20SPEAKER_01: It really is.
- 20:21SPEAKER_01: It's a way to get like a strictly honest clinical assessment of your specific imaging and history to see if modulation even makes sense for your timeline.
- 20:29SPEAKER_00: And you know, all of this raises an important question for the future, not just for brain injuries, but for how we view our bodies as a whole.
- 20:37SPEAKER_01: Oh, like what?
- 20:38SPEAKER_00: While we now know the brain's immune system can stay locked in an active, destructive state for over a decade after a single physical trauma.
- 20:47SPEAKER_01: Right.
- 20:47SPEAKER_00: It makes you wonder what other seemingly invisible, long-forgotten physical triggers in our lives might be permanently altering our body's internal state without us ever realizing it.
- 20:58SPEAKER_01: That is a haunting thought.
- 20:59SPEAKER_01: That is.
- 21:00SPEAKER_01: I mean, that demolition crew might be working quietly in the background long after we think the dust has settled.
- 21:05SPEAKER_01: We focus so much on the initial impact, we completely ignore the echoes.
- 21:10SPEAKER_01: Exactly.
- 21:11SPEAKER_01: Well, thank you for joining us on this deep dive.
- 21:14SPEAKER_01: Keep questioning, keep learning, and we will catch you next time.